Anteris Technologies (AVR) AGM 2025 summary

Opening remarks and agenda

• Meeting held in hybrid format, with both in-person and virtual attendance, and included a business update, Q&A, and formal voting on proposals.

• Annual meeting held in December 2025, following a transformative year with a US IPO and re-domiciliation from Australia to the US.

• Introduction of board members, executive team, and independent auditor; meeting procedures and technical support outlined.

• New directors David St Denis, Greg Moss, and David Roberts welcomed, highlighting their healthcare and corporate experience.

Board and executive committee updates

• Board composition enhanced with directors experienced in NASDAQ healthcare and corporate governance.

• Board includes John Seaberg (Chairman), Wayne Paterson (Vice Chairman & CEO), and other experienced directors.

• Leadership team features seasoned executives with backgrounds in major MedTech companies.

• Executive team and key management roles introduced, including audit and financial oversight.

• Leadership praised for fostering a culture of innovation, resilience, and patient-focused mission.

Financial performance review

• Cash position at end of 2024 was $70.5M, dropping to $9.1M by Q4 2025.

• Capital raised in 2024 totaled $125.9M, including $88.8M from the IPO.

• R&D costs increased 66.6% year-on-year to $51.5M in 2024, with $49.6M spent in the first nine months of 2025.

• Operating spend is primarily R&D, representing 76.4% of total spend for the first nine months of 2025.

• Positive FX impact from AUD decline reduced USD expenses.